Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Austria

European Innovation Council · Running

IMPACT-OC Interpretable Multimodal Predictive Agents and Digital Twins for Ovarian Cancer

Coordinator
Danube Private University GmbH, Austria
Runs
1 October 2026 to 30 September 2030
Status
Running
EU funding
€4.0m
Total cost
—
Partners
10 organisations in 5 countries
Type
European Innovation Council
Grant agreement
101306266

What the project is doing

In the project's own words, from its summary on CORDIS.

IMPACT-OC builds an interpretable, standards-first decision-support stack not only for patients with ovarian cancer but also for indeterminate adnexal lesions and women with unknown hereditary risk for developing ovarian cancer. Calibrated modality-specific agents (imaging, pathology, genomics, clinical text) and a super-agent fuse evidence with guideline logic, site policies and explicit uncertainty to produce auditable recommendations.

A longitudinal digital twin forecasts trajectories and short what-if scenarios. Outputs surface via a clinician dashboard and report agent. Privacy-preserving scale-up is central: data stay on site; federated learning exchanges encrypted updates; safety-gated synthetic datasets support benchmarking and stress tests. All assets interoperate through DICOM/DICOMweb for imaging and HL7 FHIR/OMOP for structured data, with DCAT-AP metadata, provenance and model cards.

Multilingual NLP and adapted foundation models are packaged as lightweight services. Validation is strictly non-interventional (TRL-4), using retrospective and time-shifted feeds for internal–external testing, calibration, uncertainty quality and fairness audits across centres, scanners, languages and subgroups—without influencing care. Three pilots anchor evaluation: expertise-aware triage between primary surgery and neoadjuvant chemotherapy in advanced HGSOC; ultrasound-based preselection for HRD/BRCA testing; and calibrated multimodal risk for adnexal-mass management.

Data access from four European centres enables a three-period plan: foundations (ethics, harmonisation, baseline agents), integration (digital twin v1, dashboards, shadow-mode replay) and final validation (explainability, robustness, fairness). Outputs—open interfaces, interoperability profiles and CE-readiness materials—support adoption by hospitals and SMEs, aligned with the EU AI Act, Medical Device Regulation, EUCAIM and EHDS.

Topics

Who is involved

OrganisationCityCountryRole
Danube Private University GmbHKrems-SteinAustriaCoordinator
Duervation GmbHKrems an der DonauAustriaParticipant
Ecoplus.niederosterreichs Wirtschaftsagentur GmbHSt PoltenAustriaAssociatedpartner
Karlsruher Institut Fuer TechnologieKarlsruheGermanyParticipant
Nec Laboratories Europe GmbHHeidelbergGermanyParticipant
Ruprecht-Karls-Universitaet HeidelbergHeidelbergGermanyParticipant
Institut Regional Du Cancer De MontpellierMontpellier Cedex 5FranceParticipant
Fondazione Policlinico Universitario Agostino Gemelli IrccsRomaItalyParticipant
Politecnico Di MilanoMilanoItalyParticipant
The Chancellor Masters and Scholars of the University of CambridgeCambridgeUnited KingdomParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI